Us Exocrine Pancreatic Insufficiency Diagnostics Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Exocrine pancreatic insufficiency occurs when the pancreas does not produce enough digestive enzymes, leading to malabsorption and nutritional deficiencies. Diagnostics available in the United States cover fecal elastase testing, imaging-based assessments, direct function tests, and serological panels used to confirm and stage the condition. The US market is valued at approximately $2.647 billion in 2026, representing steady expansion from prior years and a consistent upward trajectory since 2023.

• •North America holds the largest share of the global EPI diagnostics market, with roughly 47.7 percent of worldwide revenue recorded in 2023
• •The US market was valued at approximately $2.15 billion in 2023 and is tracking toward approximately $4.25 billion by 2033 on a roughly 7 percent compound annual growth path
• •Growth reflects increasing disease recognition, an aging population, and broader screening practices across gastroenterology and primary care settings

The market is propelled by rising incidence of conditions that cause or worsen EPI, including chronic pancreatitis, cystic fibrosis, pancreatic cancer, and long-standing Type 1 and Type 2 diabetes. An aging demographic profile in the United States amplifies demand, as EPI prevalence increases with age and comorbid disease burden. Greater clinical awareness and improved diagnostic protocols are encouraging earlier detection, particularly in outpatient and primary-care environments.

• •The elderly population, who face higher rates of pancreatic disease and enzyme insufficiency, continues to expand in the United States and drives higher diagnostic test volumes
• •Advancements in less-invasive diagnostic technologies, such as fecal elastase immunoassays, are reducing barriers to testing and boosting adoption across a wider range of clinical settings
• •Growing numbers of patients on long-term pancreatic-affecting medications and post-surgical patients, including those who have undergone bariatric or oncologic procedures, are expanding the addressable testing population

The market is broadly segmented by test type, including fecal elastase testing, radiology and imaging-based diagnostics, direct pancreatic function tests, and serological assays, with fecal elastase commanding the largest share due to its non-invasive profile and clinical convenience. End-user segmentation spans hospitals, ambulatory surgical centers, diagnostic laboratories, and specialty clinics, with hospital-based testing currently dominating test volume. Geographically, the United States anchors the North American region, which collectively held approximately 47.7 percent of global EPI diagnostics revenue in 2023, far outpacing other regions.

• •Fecal elastase-1 testing is the most widely adopted diagnostic modality in the US, favored for its simplicity, non-invasiveness, and strong correlation with exocrine pancreatic function
• •Hospital laboratories and gastroenterology clinics together account for the majority of test volumes, while point-of-care and home-based testing represent an emerging and growing channel
• •Canada and Mexico contribute to the broader North American market, though the United States represents the dominant revenue contributor by a wide margin

Who are the notable companies in the industry?

The US EPI diagnostics market is moderately fragmented, with a mix of large integrated diagnostic companies, laboratory service networks, and smaller specialty diagnostic firms offering niche assay-based solutions. The technology landscape spans immunoassay-based fecal elastase tests, imaging-based evaluations, and direct stimulation procedures, each serving distinct clinical decision points. Regional capacity is concentrated in major metropolitan areas and academic medical centers, where advanced diagnostic infrastructure and specialist referral networks are most deeply established.

• •The competitive structure features a combination of full-service integrated diagnostics providers with broad laboratory menus and focused specialty firms concentrating on gastroenterology-specific assay offerings
• •Primary technology and process routes include fecal elastase immunoassays for initial screening, cross-sectional imaging and endoscopic ultrasound for anatomical evaluation, and direct pancreatic function tests such as secretin stimulation for confirmatory assessment
• •Diagnostic capacity and test volume are heavily concentrated in the Northeast, Midwest, and major population centers of the South and West, corresponding to regional hospital density and gastroenterology specialist availability

What are the recent trends and outlook?

Point-of-care and at-home sample collection options are gaining traction, particularly for fecal elastase testing, as patients and providers seek alternatives to traditional centralized laboratory visits. Advances in molecular and genomic diagnostics are opening pathways for earlier identification of genetic conditions associated with EPI, such as cystic fibrosis, broadening the diagnostic toolkit beyond enzyme-based testing. The market is expected to sustain a compound annual growth rate of approximately 7.18 percent through the mid-2020s, supported by continued clinical adoption of non-invasive protocols and expanding managed-care coverage for diagnostic testing.

• •Digital health platforms and remote sample collection services are lowering access barriers and enabling earlier diagnosis, particularly in rural and underserved populations
• •Emerging biomarker research and next-generation sequencing applications may introduce more precise stratification tools for patients with underlying genetic predispositions to EPI
• •Reimbursement policy changes and expanded insurance coverage for EPI-specific diagnostic codes are anticipated to further accelerate testing rates and market expansion